EMUC22 Preview: “Treatment intensification in mHSPC is a hot topic right now”

In this article, world-renowned cancer researcher and EMUC22 Steering Committee member Prof. Silke Gillessen (CH) shares her personal programme highlights in an interview about the upcoming congress.

In your expert opinion, what are the most relevant topics at EMUC22 and why?

Prof. Gillessen: This is difficult to decide because they are all relevant, but my choice would be perioperative systemic therapy for urothelial cancer, because there are a lot of new potential options, but no new clear standards yet, and some conflicting evidence. Hence, there is a lot to discuss on this topic.

Treatment intensification in mHSPC is also a hot topic right now because there are so many new treatment options. It is not yet clear who needs triplet therapy, and it is also not yet clear if there are patients for whom we can de-intensify treatment.

Lastly, the topic of tailored treatment in kidney cancer. It is important for less frequent forms of RCC including non-clear cell RCC or for hereditary kidney cancer. For ccmRCC there are many possible first line options and it is important to look at how to best select patients.

What are your top three personal highlights of the programme?

Prof. Gillessen: There are many good sessions, but my personal highlights are: Firstly, Plenary Session 3: New strategies in bladder cancer, which will include many interesting discussions on urinary markers, bladder preservation strategies, molecular subtyping and selecting optimal candidates for adjuvant therapy (this is a big open question).

Another highlight is Plenary Session 5: New trials results, which will offer short, concise updates about the most important trials in the field critically discussed by a specialist. It is always interesting to have a critical view on important, practice changing data.

There is a great opportunity to have specialists from different disciplines discuss complex cases in Plenary Session 10: Multidisciplinary sessions for aggressive prostate cancer.

Registration is still open and the dynamic four-day scientific programme will delve into the latest developments in the prevention, diagnosis and management of genito-urinary (GU) cancers.

How to join EMUC22
You can register now to participate in EMUC22 here. For the complete scientific programme, please click here.

ESUI22
The 10th meeting of the EAU Section of Urological Imaging (ESUI22) will take place on the 10th of November in conjunction with EMUC22. Delegates can expect extensive assessments of technological applications in imagine-guiding approaches. ESUI22 will also investigate how imaging enhances urological diagnostics and intraoperative visualisation, and helps define the standardisation of the reporting of urological cancers.